Health ❯ Healthcare ❯ Clinical Research

Drug Trials

Efficacy Studies Eli Lilly GLP-1RA Studies Semaglutide for Smoking Cessation Real-World Studies Weight Management Studies Apitegromab Novo Nordisk Study FIND-CKD Study Personalized Treatments

Oral Semaglutide Linked to Fewer Heavy Drinking Days in Small Randomized Trial

The result points to oral semaglutide as a potential harm‑reduction option pending larger trials and regulatory review.

New Data Show Lower Activity, Muscle Loss and Mood Changes Linked to GLP‑1 Weight Drugs

Finerenone Slows Kidney Decline in Non‑Diabetic CKD, Trial Shows

New Trials Show Daily Pills Can Help Maintain Weight Loss After GLP-1 Injections

Anvisa Logs 65 Suspected Deaths Linked to GLP-1 Weight-Loss Injections in Brazil

Brazil Approves Twice-Yearly Lenacapavir Injection for HIV Prevention

Brazil Authorizes Leqembi for Early-Stage Alzheimer’s Treatment

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Sanofi, Dren Bio Set Autoimmune Collaboration Worth Up to $1.7 Billion With $100 Million Upfront

Novo Nordisk Halts Phase-3 Alzheimer’s Trial of Semaglutide After Failure to Slow Decline

Study Finds Women Hold Greater Genetic Risk for Major Depression Than Men

Niraparib Add-On Slows Progression in Advanced Prostate Cancer, Phase III Trial Shows

FDA Clears Novartis' Rhapsido, First Oral BTK Inhibitor for Chronic Hives

AbbVie Extends Rinvoq U.S. Exclusivity to 2037 as AI Biotechs Move From Models to Medicines

Leqembi Launches in Germany for Early Alzheimer’s Patients

FDA Approves Vizz Eye Drops for Presbyopia

EMA Recommends Restricted Approval for Eli Lilly’s Alzheimer’s Drug Kisunla

New Injection Shows Promise as First Major Asthma and COPD Treatment Breakthrough in 50 Years

Semaglutide Shows Significant Cardiovascular Benefits for Heart Failure Patients

New Alzheimer's Drugs Face Scrutiny Over Efficacy and Safety